this post was submitted on 23 Jul 2024
4 points (100.0% liked)

World News

32283 readers
661 users here now

News from around the world!

Rules:

founded 5 years ago
MODERATORS
you are viewing a single comment's thread
view the rest of the comments
[–] [email protected] 1 points 3 months ago (3 children)

In a study presented at the 25th international Aids conference in Munich on Tuesday, experts calculated that the minimum price for mass production of a generic version, based on the costs of lenacapavir’s ingredients and manufacturing, and allowing for 30% profit, was $40 a year , assuming 10 million people used it annually. In the long-term, 60 million people would probably need to take the drug preventatively to lower HIV levels significantly, they said.

Accounting for 30% profit seems reasonable to me.

Yet they're selling it for 1000x the price.

I understand they need to recoup research costs, but...

I have no other words.

[–] [email protected] 1 points 3 months ago

The research cost recovery line they often yap about is bullshit itself though. The overwhelming majority of pharma research like the one involved here is subsidized through taxpayer dollars already, and they get tax incentives and write offs for failed research. If we had a sane, working government we could nationalize all life saving medications funded by public money while still allowing the inventors to enjoy some (reasonable) economic benefits from the research

load more comments (2 replies)